PDCD1 and head and neck squamous cell carcinoma: Treatment with the PD-1 targeting antibodies pembrolizumab (Keytruda®, Merck & Co., Inc., US) or nivolumab (Opdivo®, Bristol-Myer Squibb, US) achieved durable antitumor activity in recurrent and/or metastatic HNSCC.